Alts Watch Healthcare Beat: $1.1bn supporting novel therapies, T-cell research

New treatments for cancer, rheumatoid arthritis and diabetes are on the horizon thanks to a series private capital deals over the past week.

Alternative investment firms leading the way were: H.I.G. Capital; BlackRock; Surveyor Capital (a Citadel company); New Enterprise Associates; Deerfield Management and Bain Capital Life Sciences.

Below is our weekly run-down of all healthcare-oriented deals $40 million and up for the week ending January 31.

BridgeBio Pharma

  • The deal: $400 million in convertible senior notes.
  • The players: Aiming to attract . . .

    Continue Reading

    Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available. Research articles require an Annual sub.

    Get started

Related Articles

Back to top button

Start Your Days in the Know

 

Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!